The U.S. Food and Drug Administration (FDA) has approved GE Healthcare’s molecular imaging agent AdreView™ (Iobenguane I 123 Injection) for the detection of rare neuroendocrine tumors in children and adults. The product provides images of high quality that assist physicians in the detection of tumors, at the initial stage as well as at the time when relapse is suspected. AdreView™ marks an advancement in diagnosis of cancer patients suffering from neuroblastoma. It will also identify primary and metastatic pheochromocytoma.

Syntermed, Inc.’s SyncTool™, a diagnostic tool for heart failure, has been exclusively licensed by GE Healthcare for new Xeleris workstations in combination with Syntermed’s Emory Cardiac Toolbox™ (ECTb). GE is also offering the software as an upgrade to existing customers that examines the advantages of cardiac resynchronization therapy (GE Healthcare) in patients suffering with heart failure. This will make nuclear cardiology more efficient and accurate. Syntermed also introduced a range of novel solutions for nuclear cardiology, such as ReconTools™ that will enhance diagnostic capabilities, and Syntermed Live™ which advances imaging workflow.

General Electric Co.’s GE Healthcare unit has received FDA approval of its LightSpeed CT750 HD, the first high-definition computed tomography (CT) scanner. According to the company, the product improves image quality while reducing dose by up to 50% across the entire body and by as much as 83% for cardiac scans.